Biocon Ltd informed in an exchange filing on Sunday that the Johor Bahru unit of the company's subsidiary Biocon Biologics in Malaysia has received a Voluntary Action Indicated (VAI) from the US Drugs and Food Administration (US FDA). The unit was inspected from 15–27 September 2024. The company said in the exchange filing, "The US Drugs and Food Administration (US FDA) has classified Biocon Biologics' insulin facility in Johor Bahru, Malaysia as Voluntary Action Indicated (VAI)."

The company said that this is related to the cGMP inspection conducted by the agency between September 15 and 27, 2024. The scope of the inspection included several biologics manufacturing units. Recently, Biocon's subsidiary Biocon Biologics Limited has announced the completion of its first year as a fully integrated biosimilar enterprise after the acquisition of Viatris in 2022. Stock performance The company's stock closed 2.71 per cent down at Rs 360.50 on Friday. In the last one year, the company's stock has seen a rise of 31.47 per cent.